Document Detail


In vivo targeting of acute myocardial infarction with negative-charge, polymer-modified antimyosin antibody: use of different cross-linkers.
MedLine Citation:
PMID:  9420759     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Cell surfaces and intercellular matrixes contain acidic residues, making them negatively charged. Antibodies are basic, positively charged glycoproteins. Therefore the potential for nonspecific ionic interaction exists, which could increase the background activity. Modification of antibodies with negatively charge-modified polymers have been shown to reduce this nonspecific background activity. This study was performed to investigate the appropriateness of different cross-linkers used covalently to link the chelating negatively charge-modified polylysine to antimyosin Fab (AM-Fab). The cross-linking was performed through peptide (AM-I) or thioether (AM-II) bonds. The in vitro evaluation of the immunointegrity and the in vivo assessment were performed to investigate the potential for reduction of nontarget background activity. Furthermore, the role of the charge of the polymers (whether completely negatively charge modified by succinylation [AM-IIs] or only partially negatively charge modified [AM-IIns]) was also assessed. METHODS AND RESULTS: All polymer-modified preparations (AM-I, AM-IIs, and AM-IIns) retained the immunoreactivities relative to the unmodified or conventional diethylenetriaminepentaacetic acid-coupled AM-Fab as assessed by radioimmunoassay or enzyme-linked immunosorbent assay. These polymer-modified preparations labeled with 111In were assessed in 13 rabbits with acute experimental myocardial infarction. Acute infarcts were produced by 40 minutes of left anterior descending coronary artery occlusion followed by reperfusion. At between 10 and 30 minutes of reperfusion, 10.4 +/- 1.8 mBq 111In-AM-I (10 to 20 micrograms; n = 7) or 11.4 +/- 2.3 mBq 111In-AM-II (n or ns) (20 to 25 micrograms; n = 6) was administered intravenously. Gamma imaging was performed in the left lateral position and arterial blood samples were withdrawn serially for the next 3 hours. At the end of the final imaging session, AM-I uptake was determined to be 1.09% +/- 0.11% (mean percent injected dose per gram myocardium +/- SEM) in 20 infarcted myocardial segments from seven rabbits, compared with 0.031% +/- 0.003% in 20 normal myocardial segments (infarct/normal myocardial ratio 53.9 +/- 18.41). The mean percent injected dose of 111In-labeled thioether-linked AM-Fab preparations in nine infarcted myocardial segments from each group was 0.067% +/- 0.008% (infarct/normal myocardial ratio 9.0 +/- 1.5) and 0.144% +/- 0.011% (infarct/normal myocardial ratio 10.2 +/- 1.9) with AM-IIs (n = 3) and AM-IIns (n = 3), respectively (p < 0.0001). The non-target organ distribution of the AM-I and AM-IIs was similar. AM-IIns preparation resulted in high non-target organ activities. CONCLUSIONS: This study shows that the charge of the antibody can be manipulated favorably by cross-linking with negatively charged polymers, which results in the reduced in vivo non-target organ activities. Charge modification does not adversely affect the apparent affinity of the antibody. However, the type of cross-linkers used may significantly influence the in vivo stability of the modified antibody preparations for target organ visualization. These data may find potential application in future clinical imaging protocols.
Authors:
J Narula; V P Torchilin; A Petrov; S Khaw; V S Trubetskoy; S M O'Donnell; N D Nossiff; B A Khaw
Related Documents :
2410739 - Arachidonic acid cascade and the generation of ischemia- and reperfusion-induced ventri...
1803019 - Failure to reduce infarct size by intracoronary infusion of recombinant human superoxid...
7900869 - Transient adenosine infusion before ischemia and reperfusion protects against metabolic...
7860929 - A chimeric igg4 monoclonal antibody directed against cd18 reduces infarct size in a pri...
19353379 - Intra-cardiac remote ischemic post-conditioning attenuates ischemia-reperfusion injury ...
18716709 - Limitation of myocardial infarct size in the clinical setting: current status and chall...
21598029 - Infarct tissue characteristics of patients with versus without early revascularization ...
16392209 - A modified infarct exclusion technique for repair of anteroapical postinfarction ventri...
1629639 - The clinical usefulness of electrocardiogram-gated tc-99m methoxy-isobutyl-isonitrile i...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology     Volume:  2     ISSN:  1071-3581     ISO Abbreviation:  J Nucl Cardiol     Publication Date:    1995 Jan-Feb
Date Detail:
Created Date:  1998-02-06     Completed Date:  1998-02-06     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  9423534     Medline TA:  J Nucl Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  26-34     Citation Subset:  IM    
Affiliation:
Northeastern University, Boston, MA 02115, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Immunoglobulin Fab Fragments / diagnostic use*
Indium Radioisotopes / diagnostic use*
Male
Myocardial Infarction / radionuclide imaging*
Myosins / immunology*
Rabbits
Radioimmunodetection*
Tissue Distribution
Grant Support
ID/Acronym/Agency:
CA50505/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Immunoglobulin Fab Fragments; 0/Indium Radioisotopes; EC 3.6.4.1/Myosins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The value of perioperative clinical indexes and dipyridamole thallium scintigraphy for the predictio...
Next Document:  Factors influencing myocardial salvage with primary angioplasty.